Table 2 Baseline lesion and procedural characteristics.
Persistent AKI 25 (2.9%) | Transient AKI 57 (6.5%) | No AKI 795 (90.6%) | P value | |
|---|---|---|---|---|
Clinical presentation at PCI | 0.31 | |||
STEMI | 22 (88.0) | 43 (75.4) | 651 (82.5) | |
NSTEMI | 3 (12.0) | 14 (24.6) | 138 (17.5) | |
Culprit lesion | 0.11 | |||
LAD | 15 (60.0) | 28 (50.0) | 360 (45.3) | |
RCA | 6 (24.0) | 18 (32.1) | 319 (40.2) | |
LCX | 4 (16.0) | 6 (10.7) | 102 (12.9) | |
LMT | 0 (0) | 4 (7.1) | 13 (1.6) | |
Multiple vessel disease | 10 (40.0) | 18 (31.6) | 239 (30.1) | 0.56 |
Multivessel PCI with one-time strategy | 2 (8.0) | 6 (10.5) | 32 (4.0) | 0.05 |
Multivessel PCI with staged strategy | 6 (24.0) | 12 (21.1) | 193 (24.3) | 0.86 |
Killip ≥ 3 | 5 (20.0) | 12 (21.4)† | 73 (9.3)† | 0.012 |
Femoral approach | 16 (64.0) | 32 (57.1) | 364 (45.8) | 0.058 |
Contrast volume, mL | 170 (128–219) | 178 (121–232) | 184 (142–228) | 0.46 |
Contrast volume/eGFR | 3.31 (2.40–4.43) | 3.21 (2.56–4.57)† | 2.79 (2.18–3.52)† | 0.0026 |
Pre-PCI TIMI score < 3 | 23 (92.0) | 53 (94.6) | 705 (88.9) | 0.31 |
Post-PCI TIMI score < 3 | 1 (4.0) | 4 (7.1) | 47 (5.9) | 0.86 |
Mechanical circulatory assist devices, n (%) | 3 (12.0) | 14 (24.6) | 105 (13.2) | 0.08 |
Catecholamine use, n (%) | 3 (12.0) | 11 (19.3) | 103 (13.2) | 0.46 |
Bleeding BARC type ≥ 3 | 5 (20.0)* | 9 (15.8)† | 29 (3.7)*,† | < 0.0001 |
Mehran score | 10.0 (6.0–14.0)* | 11.5 (6.0–16.8)† | 6.0 (3.0–11.0)*,† | < 0.0001 |
